LDLR and atherosclerosis: In line with numerous studies and clinical trials (reviewed by Mindur and Swirski70) that show the potency of circulating growth factors and cytokines in promoting and/or limiting the development of atherosclerosis, administration of the secreted factors from GW3965‐treated EOCs significantly reduced aortic lesion development in recipient Ldlr−/− mice.